Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.)
(PRWEB) January 08, 2015
This report studies the plasma fractionation market over the forecast period of 2014-2019. The global plasma fractionation market is estimated to be worth around $16,573.4 million in 2014 and grow at a CAGR of 8.9% during the forecast period of 2014 to 2019.
Browse 126 market data tables and 38 figures spread through 200 pages and in-depth TOC on Plasma Fractionation Market.
Early buyers will receive 10% customization on this report.
The plasma fractionation market saw healthy growth during the last decade, primarily attributed to the rising ageing population, increasing number of haemophiliac patients, raising off-label use of albumin and immunoglobulins in various chronic diseases, increased diagnosis rate, and the increasing use of prophylactic treatment for bleeding disorders and disease of immune systems. However, the high cost and serious adverse effects of plasma products, and the emergence of recombinant products used as alternatives to plasma-derived products are hampering the growth of this market to a certain extent.
For Report Inquiry at http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=93798284
In this report, the plasma fractionation market is segmented by products, applications, end users, and region. Based on type of product, the plasma fractionation market is mainly segmented into albumin, immunoglobulins, coagulation factor concentrates, and others. The immunoglobulin segment is further sub-segmented into intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and others. The coagulation factor concentrates segment is divided into factor VIII, factor IX, factor XIII, prothrombin coagulation concentrates, Von Willebrand factor, and fibrinogen concentrates. The various application areas of plasma fractionation products analysed in the report include neurology, haematology, immunology, and critical care. Likewise, the major end users of this market are hospitals and clinics, clinical research laboratories, and academic institutes.
IVIg accounts for the major share of the plasma fractionation market. The increasing use of IVIg in clinical areas such as neurology, haematology, immunology, rheumatology, and dermatology, and its excellent efficacy records are the key factors responsible for the growth of this market segment. In addition, the use of IVIg in a wide range of conditions, such as adult respiratory distress syndrome, fibrosis, connective tissue disease, encephalitis, heart failure, and Alzheimer’s disease, is being evaluated. Positive results in such conditions would increase the demand for IVIg globally in the near future.
Download PDF at http://www.marketsandmarkets.com/pdfdownload.asp?id=93798284
In 2013, North America was the leading market for plasma fractionation, followed by Europe, and Asia-Pacific. The highly developed healthcare infrastructure, advent of new technologies, growing ageing population, and favourable regulatory framework in the North American and European regions has led to the large market shares of these regions. However, the highest growth opportunities for this market are in the Asia-Pacific region.
The major players in the global plasma fractionation market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.), Sanquin (Netherland) and Biotest (Germany).
Browse Related Reports:
Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General &amp; Cosmetic Surgery, Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to 2019
Freeze Drying / Lyophilization Equipment Market by Scale (Lab, Pilot, &amp; Industrial), Technology (Rotary, Manifold, &amp; Tray - style) &amp; by Accessories (Loading/Unloading System, Vacuum System, Clean-in-Place System, Control System) - Global Forecast to 2019
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 full-time analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical info graphics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog at http://mnmblog.org/market-research/healthcare/biotechnology